New Oral Weight-Loss Drug Shows Promise in Clinical Trial
A groundbreaking daily weight-loss pill named orforglipron has demonstrated greater efficacy for both weight reduction and blood sugar management than existing oral semaglutide products, according to a recent phase 3 clinical trial. This development could significantly impact the rapidly growing oral weight-loss drug market, offering a potential alternative to injectable treatments.
The Rise of GLP-1 Medications
The weight-loss drug landscape transformed several years ago with the introduction of injectable semaglutide, marketed under brand names such as Wegovy and Ozempic. Semaglutide belongs to the glucagon-like peptide-1 (GLP-1) class of medications, which mimic the gut hormone GLP-1 released after eating. This hormone signals fullness to the brain, slows digestion, and stimulates insulin release, making GLP-1 drugs highly effective for managing type 2 diabetes and promoting weight loss.
However, a major drawback of injectable semaglutide is the requirement for self-injection into areas like the belly, thighs, or back of the arm. This poses challenges for patients with needle phobia or those who find injections inconvenient. Additionally, injectable GLP-1 drugs need refrigeration throughout the supply chain, creating logistical hurdles, particularly in low- and middle-income countries where cold chain infrastructure may be unreliable.
Advantages and Limitations of Oral Semaglutide
In response to these issues, researchers have explored oral versions of semaglutide. Current studies indicate that oral semaglutide is effective but comes with significant limitations. It must be taken on an empty stomach, with users waiting 30 minutes before eating or drinking. Moreover, it has poor bioavailability, meaning only about 1% of the ingested drug is absorbed to exert its effects, and it is expensive to produce.
Orforglipron: A Superior Alternative?
The recent 52-week phase 3 trial involved 1,698 adults with type 2 diabetes across six countries, comparing oral semaglutide with orforglipron, a daily tablet. The primary measure was reduction in HbA1c, a blood test reflecting average blood sugar levels over three months, with diabetes indicated at 6.5% or higher.
From a baseline average HbA1c of 8.3%, orforglipron reduced this value by an average of 1.71–1.91% after 52 weeks, outperforming oral semaglutide, which only achieved a 1.47% reduction. Participants taking orforglipron also lost more weight, averaging 6.1kg to 8.2kg, compared to 5.3kg for those on semaglutide.
Tolerability Concerns with Orforglipron
Despite its efficacy, orforglipron presented tolerability issues. GLP-1 drugs commonly cause gastrointestinal side effects such as nausea, vomiting, diarrhea, and constipation. In this trial, approximately 59% of orforglipron participants reported such symptoms, versus 37–45% on semaglutide. This higher rate may be due to more prominent daily peak drug concentrations with orforglipron.
Consequently, around 10% of orforglipron users discontinued treatment due to adverse effects, compared to just 4–5% for semaglutide. No head-to-head trials have yet compared injectable GLP-1 drugs with orforglipron, but weight loss results in this study are broadly similar to those observed with injectable versions.
Market Implications and Drug Classification
Developed by Eli Lilly, orforglipron emerges as a credible challenger to semaglutide. Notably, it belongs to a new category called small-molecule drugs, synthetic chemical compounds small enough to be absorbed directly through the gut wall to act on GLP-1 receptors, despite not structurally resembling the GLP-1 hormone.
In contrast, oral semaglutide is a peptide drug, with amino acid structures closely mimicking natural GLP-1. As a small-molecule drug, orforglipron is cheaper and simpler to manufacture than peptide-based drugs and requires no refrigeration, offering logistical advantages for expanding access in regions with unreliable cold chain infrastructure.
Future Prospects and Challenges
While orforglipron has proven superior for blood sugar control and weight loss in this trial, its higher side-effect rate and treatment discontinuation may limit market enthusiasm. In a competitive weight-loss drug market, long-term adherence—influenced by tolerability as much as efficacy—could be a critical factor. Orforglipron is still undergoing trials in patients with obesity but without diabetes, with further research needed to fully assess its potential and limitations.
